Delivery Order SPE2DB24D1205-SPE2DB25FCZWS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with an ultimate completion date of October 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 16, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,777.00 delivery order to AmerisourceBergen Drug Corp for 100 milligram vials of Enhertu, a specialty oncology medication. This firm fixed price contract, issued on May 30, 2025, with an ultimate completion date of June 23, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreements with the federal government. The award was competitively granted without set-aside provisions and will be performed at...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $14,221.60 on June 30, 2025, for the supply of Enhertu 100 mg vials with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a pediatric-focused pharmaceutical procurement supporting federal medical supply requirements. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a Delivery Order (4569006087) valued at $8,888.50 to AmerisourceBergen Drug Corp for the supply of Enhertu 100 mg vials, with a completion date of August 27, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. The company serves as a critical vendor...
- The Defense Logistics Agency awarded a $17,777 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a oncology therapeutic agent used in cancer treatment. The contract was competitively awarded without set-aside restrictions and carries an ultimate completion date of September 24, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Enhertu 100 mg vials, a specialty oncology pharmaceutical. This firm fixed-price delivery order, valued at $8,888.50 with an ultimate completion date of August 20, 2025, represents a non-competitive set-aside transaction under AmerisourceBergen's existing contract vehicle. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,443.90 for 100 mg vials of Enhertu, a oncology therapeutic agent, with performance in Conshohocken, Pennsylvania and completion scheduled for May 13, 2025. This competitively awarded, firm fixed-price delivery order contains no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply framework with the federal government. This delivery order executes...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,666.20 for 100 mg vials of Enhertu, an oncology medication, on September 8, 2025, with completion scheduled for September 29, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Enhertu 100 mg vials, valued at $8,888.50 with a firm fixed price arrangement. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation,...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZWSDelivery Order
The Defense Logistics Agency awarded a $8,888.50 delivery order to AmerisourceBergen Drug Corp for 100 mg vials of Enhertu, a therapeutic oncology medication, with an ultimate completion date of September 17, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order exemplifies the Defense Logistics Agency's pharmaceutical procurement strategy through its Medical Supply Chain, leveraging AmerisourceBergen's comprehensive IDC to fulfill specialized medical supply requirements for military and veteran healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, maintains an extensive portfolio of federal contract awards covering a broad spectrum of therapeutic domains and medical commodities. The company's established capacity to deliver specialty medications, branded pharmaceuticals, and medical supplies through competitive federal procurement demonstrates its critical role in supporting Department of Defense healthcare operations and the broader military medical supply infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/26/25 |